After successfully selling three small molecule manufacturing plants around the world, Roche was unable to find a buyer for a site in Clarecastle, Ireland. Now, it’s set to close up there and lay off 132 workers by next year, The Irish Times reports.
Roche is already in the process of a phased exit, and the drugmaker expects the process to conclude by March 2020, the newspaper reports. The company has set aside €24 million for the employees who are still working at the site, the newspaper reports, citing Roche Ireland documents. That means each worker could be in line for a €180,000 termination payment.
In 2015, Roche unveiled a massive shift of manufacturing priorities, setting out to downsize its small molecule manufacturing capacity and bolster its biologics presence. Before that, the drugmaker announced it’d spend €800 million to expand biologics capacity at sites in Germany, Switzerland and the U.S.
As part of the moves, Roche said it would cut 1,200 jobs and exit four small molecule sites around the world. Roche ultimately found buyers for its plants in the U.S., Italy and Spain, but couldn’t sell the Ireland site, and now it’s closing up shop.
The drugmaker sold its site in Spain to Recipharm, which won a long-term deal to supply Roche with solid-dose drugs and agreed to keep 200 workers at the facility. Roche used similar contract language to sell its other plants.
Roche’s bet on biologics has been paying off as the company holds a leadership position in cancer and other diseases. But it’ll face a new test as biosimilars to its three top cancer drugs hit the U.S. market, threatening $10 billion in sales. Roche executives believe the company’s newer medicines can fill the gap created by biosimilars and add some growth.
By Eric Sagonowsky
Source: Fierce Pharma
A new survey by Clinical Research IO has found that nearly one-quarter of polled trial investigators have stopped enrolling new patients due to the COVID-19 pandemic. The survey, conducted March […]
Dive Brief: The European Commission is working on a proposal to delay enforcement of the EU Medical Device Regulation by one year, a spokesperson said Wednesday. Policymakers are aiming […]
The reality of climate change is hard to ignore. As one of the biggest polluters, and simultaneously the industry tasked with trying to tackle the global health outcomes of environmental […]
